Pregnancy
Meet the California start-up reimagining prenatal screening
Biotech start-up Juno Diagnostics is poised to support women through every step of the pregnancy journey

Born out of a need to address the problems within the US prenatal healthcare system, Juno Diagnostics is on a mission to shake up the landscape of traditional prenatal care. We speak to co-founder and chief medical officer, Dr Mathias Ehrich, and director of genetic counselling, Katie Sagaser, to find out more.
Tell us a bit more about the story behind Juno.
Mathias Ehrich: Our aim has always been to create equitable access to high-quality prenatal care. We want all women to have the opportunity to learn about their pregnancy and feel empowered to make informed decisions.
In launching the world’s first capillary-based cfDNA non-invasive prenatal screening test, we looked to create an affordable test that met our goals of accessibility and transparency.
So in 2011, the Juno co-founders and I were working together at a life sciences company to pioneer the development and commercialisation of the first cell-free DNA-based non-invasive prenatal screen (NIPS) in the United States.
There, we drove a lot of innovation in pregnancy care and prenatal care up until the company was acquired in 2016. At the time, only about 800,000 women had true access to NIPS.
So when we looked at the problem again, we found a couple of things in the market that were not working.
First of all, most NIPS tests were too expensive, and second of all, they were difficult to access. In almost 50 percent of all US counties, women don’t even have access to an OB/GYN, let alone a phlebotomy service.
So women really had a problem with getting access to NIPS technology.
That’s when we realised that we needed to develop something that we could send in the mail and that could be shipped in a box, in a cheaper and a lot more accessible way. We needed to meet women where they are.
Katie Sagaser: From my experience as a genetic counsellor, I was able to see the ways in which a new type of test is introduced, especially in the genetic testing world.
There’s a lot of ‘healthy fear’ at first, but sometimes that ends up paralysing patients in a way that if we, as folks in industry, don’t equip them with the right resources, it prevents them from being able to utilise technology that can be extremely empowering, in this case, for their pregnancy.
NIPS is not novel anymore. Yet, there are still OB-GYN providers out there who are reticent to incorporate it into their routine screening programmes for whatever reasons.
So one of the things that we have really wanted to do at Juno is work together with our providers, colleagues and partners, to try to equip them with the resources that they need to help their patients get the information that’s right for them and to ultimately, make an informed decision.
How does your approach help women access pre-natal screening tests at home?
KS: We’ve designed an extremely personalised approach because we really want to be meeting people right where they are.
At present, for the non-invasive prenatal screening test, there are two different pathways that people can follow.
They can either request the test themselves and a physician will review the order request and approve it, or their provider can order the test for them.
Once the order is placed, the patient is prompted to set up a Zoom call for a sample collection. This is going to be the same whether they’re doing the non-invasive prenatal screening test or the foetal gender test.
After the actual sample collection, patients are equipped with everything they need to return the kits. They just have to send them to the lab.
After we analyse the sample, they can access their results in their myJuno account.
What’s really unique is that our platform keeps them informed every step of the way, similar to how they might be used to tracking an order.

ME: We always wanted to empower women and encourage them to do things at their own pace. They have all the information they need on the platform and if something isn’t clear, they can get in touch with a genetic counsellor at any time of the process.
However, the platform is not a replacement for their OB-GYN provider. It’s something that’s intended to complement those services and make everybody’s life easier.
A lot of people were introduced to at-home testing during the pandemic. Do you think Covid has changed the way people view digital health?
KS: I think that prior to 2020, especially in the genetic counselling space, the whole concept of telemedicine was still intriguing. Covid has definitely changed that.
However, I think there are still challenges in the United States pertaining to our maternal health crisis and our OB-GYN access that telehealth on its own is not going to instantly fix.
ME: I think the pandemic did bring about a pretty big shift in the minds of the providers and they started to become more open to things like telehealth and taking care of patients remotely.
You’ve launched three products in 2022. What feedback have you received so far?
KS: The feedback has been exceptionally positive. I have been helping out with some of the Zoom calls on the collection side and people really appreciate the kind of support that we offer.
First of all, they like the fact that they’re talking with a real person in real time, but they also like that when they have questions, they don’t feel like a burden, and they can seek help and express their concerns.
Currently, the tests are only available in the US. Are you considering expanding your services globally?
ME: We’re extremely proud of all the work that we did in 2022. Yes, as we continue to grow, we’re considering expanding beyond the US when the time is right and in a way that is most appropriate.
It’s not Europe! I think Europe will be on our list at some point as well, but it is a little bit more difficult since most European countries have very particular healthcare systems to navigate. We promise it’s something exciting, though!
For more info, visit junodx.com.
Pregnancy
Women should not be pressured into an ‘ideal birth’, says health secretary

Women should not feel pressured into an “ideal birth”, health secretary Yvette Cooper has said as she promised major maternity reform.
Cooper has returned to the Department of Health and Social Care 27 years after serving as public health minister under Tony Blair.
She said maternity and child health would be a major focus of her new role, alongside significant reforms to social care.
In an interview with the Guardian, Cooper said the changes should address any pressure on women to pursue a particular birth experience.
Families affected by maternity failures have repeatedly raised concerns that some units were reluctant to escalate medical interventions because of a preference for more natural births.
Cooper said: “I would worry about any mum feeling pressurised that there is somehow a kind of an ideal birth experience to live up to when it’s always different in every case, and you have to follow the evidence, you have to have informed choice.”
As one of her first actions as health secretary, Cooper said she intended to reintroduce binding national maternity standards.
The standards were dismantled during early Conservative NHS reforms and replaced with fragmented arrangements managed separately by individual hospital trusts.
A new maternity taskforce will draft the standards, which will have five central aims.
These include ending regional differences in levels of care and tackling racial inequalities linked to poorer outcomes in deprived areas, particularly for Black and Asian women.
Patient experiences will also form part of how standards are measured, while new targets will aim to identify underperformance before a major scandal develops.
Cooper, who became the first minister to take maternity leave while serving as a junior health minister in the early 2000s, said reports into maternity scandals had been “traumatic” to read and showed that systemic change was needed.
She said: “We’ve always said the NHS is about the cradle to the grave. I want to make it a personal crusade to put the cradle back at the heart of the NHS, and to have much more focus around maternity and child health, the very beginning of a family’s life, making that much more central to the priorities of the NHS, giving it the priority that it really deserves.”
Cooper said discussions about how maternity services could better listen to mothers’ needs had been taking place for the past two decades.
However, she said the emphasis on placing women and families at the centre of care appeared to have been lost.
She said: “It feels incomprehensible that we could be in this situation in the 2020s. I went back to look at some of the things that we’d done 25 years ago.
“And what did strike me was how much we were talking then about women and families being at the centre of care and about listening to women’s views.
“It is really shocking and distressing feeling that has somehow been lost in some of the maternity units where actually it should be the central issue.
“I had a direct interest. I was pregnant at the time. But I am really struck by it now, just feeling like there is this big gap in the priorities that the NHS has been focused on.”
Cooper said she was determined to provide a robust response to Donna Ockenden’s investigations into maternity failures at Shrewsbury and Telford and Nottingham, alongside Baroness Valerie Amos’s national investigation into England’s maternity system.
The investigations highlighted systemic clinical errors, understaffing and toxic institutional cultures. They found that hundreds of infant and maternal deaths were directly linked to failures to listen to mothers and defensive attempts to protect institutions.
Amos’s review faced criticism, including the resignation of an expert adviser over the lack of explicit warnings about “normal birth ideology”.
Families also questioned whether the review’s proposed statutory maternity commissioner would have sufficient independence.
Cooper said she remained committed to introducing the role.
She said: “In the end, the most important people in the maternity services are the mothers, babies, the families. But the point of having a maternity commissioner is to make sure that those issues are championed as part of an NHS.”
She also said reforms needed to address an oppositional culture between doctors and midwives in some trusts over when medical intervention during birth may be necessary.
Cooper said: “The thing that struck me most was the sense of women feeling they weren’t being listened to … And I think that probably does go back to issues around culture.”
Cooper, who served as foreign secretary until recently, said she was prepared for a difficult period in the health role as she sought to implement Andy Burnham’s social care reforms.
She said she remained committed to establishing the national care service announced by the prime minister the previous week.
A longstanding ally of former prime minister Keir Starmer and a former rival of Burnham in the 2015 Labour leadership contest, Cooper said she believed the change of prime minister had been necessary.
She said: “Of course it’s not easy. I really did not think it was possible to win the election when I came back into the shadow cabinet in 2022. It’s only because of what Keir did that we managed to win.
“But we had very difficult local election results … we have to respond to that. But I think we’ve got a sense of energy now.
“All of the things that Andy wants to focus on and drive are also just very much the things that that people are concerned about across the country.”
Pregnancy
Beetroot juice may benefit pregnant women with chronic kidney disease – study

Daily beetroot juice may help support kidney health during pregnancy in women with chronic kidney disease, early research suggests.
Pregnancy puts additional strain on the kidneys. Around half of women with moderate to severe chronic kidney disease experience a decline in kidney function while pregnant.
Despite these risks, outcomes for pregnant women with the condition have changed little over the past 30 years.
Many medicines used to manage kidney disease are also unsuitable during pregnancy, meaning women often need to stop taking them for at least nine months.
Researchers at King’s College London examined whether dietary nitrate from beetroot juice could offer a simple and safe way to support kidney function during pregnancy.
Beetroot juice is naturally rich in nitrate, which the body converts into nitric oxide. Nitric oxide widens blood vessels and improves blood flow, which could reduce the strain placed on the kidneys during pregnancy.
The study involved 108 pregnant women with stage 2 to 5 chronic kidney disease across eight UK hospitals.
Before reaching 25 weeks of pregnancy, participants were randomly assigned to receive either standard care or a daily beetroot juice supplement containing dietary nitrate.
The study was mainly designed to assess whether a larger clinical trial would be practical. However, the findings also suggested possible benefits for mothers and babies.
Kate Bramham, consultant nephrologist at King’s College Hospital, professor at King’s College London and senior author of the study, said: “For women living with chronic kidney disease, pregnancy has always meant navigating a difficult trade-off between preserving their own health and keeping their baby safe, often with few tools to do both.
“These results are an encouraging first step towards a low-cost, low-risk intervention that could genuinely make a difference for this group of women, who have been underserved by research for far too long.”
Women receiving beetroot juice experienced around 70 per cent fewer serious adverse events overall than those receiving standard care. Of the serious adverse events that occurred, around half affected newborn babies.
Among women with more advanced kidney disease, researchers also observed trends towards better kidney function after pregnancy, fewer newborn admissions to neonatal care and a reduced need for blood pressure medication during pregnancy.
The researchers found no safety concerns linked to beetroot juice supplementation during pregnancy, including no increase in hyperkalaemia, which means unusually high potassium levels in the blood.
There have been concerns that beetroot juice could increase the risk of hyperkalaemia in pregnant women with chronic kidney disease, with some online advice recommending that they avoid it. However, no increase was recorded among women receiving the supplement.
Dr Priscilla Smith, a nephrologist, King’s College London PhD student and first author of the study, said: “Pregnancy can put additional stress on the kidneys, and for women with chronic kidney disease there are currently limited options to protect kidney function during this time.
“Our findings suggest beetroot juice could offer a simple and accessible approach that is safe and worth exploring further.”
The researchers said larger clinical trials are now needed to determine whether beetroot juice can significantly reduce kidney function decline and improve long-term outcomes for mothers and babies.
If confirmed, the intervention could offer an inexpensive and widely available way to support women with chronic kidney disease during pregnancy, when safe treatment options remain limited.
The research was supported by funding from Kidney Research UK.
Dr Andrew Webb, clinical senior lecturer at King’s College London and a co-author of the study, said: “By increasing nitric oxide production, dietary nitrate from beetroot juice may help improve blood vessel function and support kidney health.
“These early findings provide an important foundation for future research into protecting women with chronic kidney disease during pregnancy and their babies.”
Pregnancy
Hospital admissions for ectopic pregnancy rising in England, study suggests

Ectopic pregnancy admissions have risen in England since 2021, according to a 20-year analysis of NHS data.
Women in the most deprived areas had more than twice the admission rate of those living in the least deprived communities.
The study was the first 20-year national analysis of NHS England data on the issue.
Dr Nicola Tempest, academic clinical lecturer in the University of Liverpool’s Department of Women’s and Children’s Health, said: “Pregnancy loss affects millions of women worldwide, yet we know surprisingly little about how its prevalence and impact has changed over time.
“Our research shows that admissions for ectopic pregnancy have continued to rise despite declining birth rates, highlighting an ongoing demand for NHS services.
“Women from the most deprived areas consistently experienced much higher admission rates for both miscarriage and ectopic pregnancy, underlining persistent health inequalities.
“Pregnancy loss should be recognised as a major women’s health research priority so we can better understand its causes and develop services that meet women’s needs and address the risk factors that are contributing to these rates.
“Importantly, research must address one of the most common and deeply personal questions women ask after pregnancy loss: ‘Why did this happen to me?’”
Ectopic pregnancy is one of the most common early pregnancy complications, with an estimated 11,000 hospital admissions each year, or around one in every 90 pregnancies.
It occurs when a fertilised egg implants outside the womb. Ectopic pregnancies result in pregnancy loss and can put the mother’s health at risk if the pregnancy continues.
Researchers at the University of Liverpool analysed hospital and maternity services data collected between 2004 and 2024.
Admissions rose significantly from 2004 to 2012, increasing by an average of around three per cent each year.
Rates remained broadly stable from 2012 to 2021 before rising significantly again.
Since 2021, admissions have increased by an average of more than four per cent a year.
The researchers said the recent rise may reflect demographic changes, including women having children later and higher rates of risk factors such as obesity.
Disruption to hospital and maternity services during the Covid-19 pandemic may also have contributed.
The study also found that miscarriage admissions fell significantly between 2018 and 2021. They rose modestly in subsequent years, although the increase was not statistically significant.
A result is statistically significant when researchers consider it unlikely to have occurred through chance alone.
For more than a decade, women in the most deprived communities had more than twice the hospital admission rate for miscarriage and ectopic pregnancy compared with those in the least deprived areas.
The researchers pointed to preventable inequalities in health, risk factors and access to care as likely contributors.
Tempest said: “These findings show that where a woman lives continues to have a profound influence on her reproductive health outcomes.
“Ultimately, reducing these inequalities will require an equity-focused approach that combines high-quality clinical care with prevention, education and services designed around the needs of the communities most at risk.
“Behind every admission for pregnancy loss, there is a woman, a family and an unanswered question, our aim and mission is not only to improve the care but also to understand and prevent it.”
Entrepreneur2 weeks agoFertility startup American Baby Company secures US$4m
Fertility2 weeks agoNatural Cycles receives sixth FDA clearance for fertility algorithm
Cancer5 days agoCancer patient receives ‘landmark’ treatment in world-first
Insight2 weeks agoExperimental treatment significantly slows progression of fatal brain disease in women, study finds
Sponsored Content1 week agoThe room is filling up at WHW Europe 2026 with super early bird pricing ending this Friday
News1 day agoUK femtech investment surges 194% in a decade, research finds
Insight1 week agoJohnson & Johnson offers to pay US$5.5bn to settle talc cancer lawsuits
News2 weeks agoPlanetary Health Diet lowers heart risk in older women, study finds













Pingback: California biotech start-up shuts down commercial operations - FemTech World